WASHINGTON, April 19, 2021 /PRNewswire/ -- The Access to
Comprehensive Genomic Profiling Coalition (ACGP) announced today
the addition of AstraZeneca, Loxo Oncology at Lilly, and Invitae
Corporation (NYSE: NVTA) to its coalition of companies advocating
for appropriate coverage of comprehensive genomic profiling (CGP)
for patients living with advanced cancer by U.S. health
insurers.
"The addition of AstraZeneca, Loxo Oncology at Lilly, and
Invitae to ACGP expands our growing broad-based stakeholder
coalition and affirms our shared commitment to advocate for access
to comprehensive genomic profiling for patients living with
advanced cancer," said Jim Almas, MD, vice president and
national medical director of clinical effectiveness
at Labcorp, and the chairman of ACGP. "These three companies
are recognized as exceptional leaders in the field of oncology and
we are pleased to have them join us as part of ACGP."
CGP testing performed soon after a diagnosis of advanced cancer
better informs medical management, including treatment decisions
and patient care, which can improve clinical outcomes. In
advocating for coverage of CGP, ACGP will educate health insurers
and other healthcare stakeholders about the clinical utility and
value of CGP.
All companies that offer CGP tests or offer a product with a CGP
companion diagnostic are eligible for consideration of membership
in ACGP. If you are interested in learning more about becoming a
member, please contact us here.
About Loxo Oncology at Lilly
Loxo Oncology at Lilly was created in December 2019, combining the Lilly Research
Laboratories oncology organization and Loxo Oncology, which was
acquired by Lilly in early 2019. Loxo Oncology at Lilly brings
together the focus and spirit of a biotech with the scale and
resources of large pharma, with the goal of rapidly delivering
impactful new medicines for people with cancer. Our approach
centers on creating new oncology medicines that unequivocally work
early in clinical development and will matter to patients.
About Invitae Corporation
Invitae Corporation (NYSE: NVTA) is a leading medical genetics
company whose mission is to bring comprehensive genetic information
into mainstream medicine to improve healthcare for billions of
people. Invitae's goal is to aggregate the world's genetic tests
into a single service with higher quality, faster turnaround time,
and lower prices. For more information, visit the company's website
at invitae.com
About the Access to Comprehensive Genomic Profiling
Coalition
Access to Comprehensive Genomic Profiling (ACGP) is a
collaborative coalition of leading molecular diagnostics companies
and laboratories that aims to raise awareness about comprehensive
genomic profiling (CGP) for patients living with advanced cancer.
The coalition full members are Exact Sciences, Foundation Medicine,
Illumina, Invitae, Labcorp, NeoGenomics, QIAGEN, Roche, Tempus, and
Thermofisher. The coalition's associate members are AstraZeneca and
Loxo Oncology at Lilly.
For more information, visit: http://www.accesstoCGP.com
View original
content:http://www.prnewswire.com/news-releases/astrazeneca-loxo-oncology-at-lilly-and-invitae-corporation-join-the-access-to-comprehensive-genomic-profiling-coalition-301270830.html
SOURCE Access to Comprehensive Genomic Profiling